Chronic ocular graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 199-206

  Kim, Stella K ^a   Smith, Janine A ^b   Dunn, James P ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857234802     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.019     Document Type: Chapter

References (71)

1. Lawley TJ, et al. Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med, 1977; 87(6):707-709.
2. Franklin RM, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology, 1983;90(1):4-13.
3. Hirst LW, et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol, 1983;101(4):580-584.
4. Arocker-Mettinger E, et al. Manifestations of graft-versus-host disease following allogenic bone marrow transplantation. Eur J Ophthalmol, 1991;1(1):28-32.
5. Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 2005. 11(12):945-956.
6. Shulman HM, et al. Histopathologic diagnosis of chronic graft- versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant, 2006;12(1):31-47.
7. Schultz KR, et al. Toward biomarkers for chronic graft-ver- sus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant, 2006;12(2):126-137.
8. Pavletic SZ, et al. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant, 2006;12(3):252-266.
9. Couriel D, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, 2006;12(4):375-396.
10. Martin PJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biol Blood Marrow Transplant, 2006;12(5):491-505.
11. Jack MK, et al. Ocular manifestations of graft-v-host disease. Arch Ophthalmol, 1983;101(7):1080-1084.
12. Jabs DA, et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol, 1989;107(9):1343-1348.
13. Ogawa Y, et al., Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol, 1999;83(10):1125-1130.
14. Livesey SJ, Holmes JA, Whittaker JA. Ocular complications of bone marrow transplantation. Eye, 1989;3(pt 3):271-276.
15. Tichelli A, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant, 1996;17(6):1105—1111.
16. Calissendorff B, el Azazi M, Lonnqvist B. Dry eye syndrome in long-term follow-up of bone marrow transplanted patients. Bone Marrow Transplant, 1989;4(6):675-678.
17. Mencucci R, et al. Ophthalmological aspects in allogenic bone marrow transplantation: Sjogren-like syndrome in graft-versus- host disease. Eur J Ophthalmol, 1997;7(1):13—18.
18. Kim SK. Ocular Graft versus Host Disease, in Cornea, J.H. Krachmer, M. J. Mannis, and E. J. Holland, Editors. 2004, Mosby: St. Louis. p. 879-885.
19. Dunn JP, et al. Bone marrow transplantation and cataract development. Arch Ophthalmol, 1993;111(10):1367-1373.
20. Cheng LL, et al. Graft-vs-host-disease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. Am J Ophthalmol, 2002;134(2):293-295.
21. Fawzi AA, Cunningham, Jr., ET. Central serous chorioretinopathy after bone marrow transplantation. Am J Ophthalmol, 2001;131(6):804-805.
22. Kim RY, et al. Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol, 2002;133(6):843-845.
23. Hettinga YM, et al. Anterior uveitis: a manifestation of graft- versus-host disease. Ophthalmology, 2007;114(4):794-797.
24. Sheidow TG, et al. Vitritis as the primary manifestation of graft-versus-host disease: a case report with vitreous cytopathol- ogy. Can J Ophthalmol, 2004;39(6):667-671.
25. Jabs DA, et al. The eye in bone marrow transplantation. II. Histopathology. Arch Ophthalmol, 1983;101(4):585-590.
26. Robinson MR, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant, 2004;33(10):1031-1035.
27. Karwacka E, et al. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation. TransplantProc, 2006;38(1):292-294.
28. Kim SK, et al. Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of Stage III and IV ocular GVHD. Biol Blood Marrow Transplant, 2006;12(2 (S1)):49.
29. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea, 2003;22(Suppl 7):S19-S27.
30. Johnson DA, Jabs DA. The ocular manifestations of graft-versus- host disease. Int Ophthalmol Clin, 1997;37(2):119-133.
31. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf, 2005;3(4):203-211.
32. Kim SK. Ocular graft vs. host disease. Ocul Surf, 2005;3 (Suppl 4):S177-S179.
33. Kaiserman I, Or R. Laser photocoagulation for central serous retinopathy associated with graft-versus-host disease. Ocul Immunol Inflamm, 2005;13(2-3):249-256.
34. Moon SJ, Mieler WF. Retinal complications of bone marrow and solid organ transplantation. Curr Opin Ophthalmol, 2003;14(6):433-442.
35. Coskuncan NM, et al. The eye in bone marrow transplantation. VI. Retinal complications. Arch Ophthalmol, 1994; 112(3):372-379.
36. Armitage JO. Bone marrow transplantation. N Engl J Med, 1994;330(12):827-838.
37. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol, 2006;17(4):344-348.
38. Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 2003;13(3):176-181.
39. West RH, Szer J, Pedersen JS. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: the role ofcon- junctival biopsy. Aust NZ J Ophthalmol, 1991;19(3):187-191.
40. Wagner JE, Jr., Vogelsang GB, Beschorner WE. Pathogenesis and pathology of graft-vs.-host disease. Am J Pediatr Hematol Oncol, 1989;11(2):196-212.
41. Ogawa Y, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci, 2001;42(1):111-119.
42. Ogawa Y, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci, 2003;44(5):1888-1896.
43. Ogawa Y, et al. Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. Invest Ophthalmol Vis Sci, 2005;46(12):4519-4527.
44. Rojas B, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res, 2005;81(3):313-325.
45. Aronni S, et al. Upregulation of ICAM-1 expression in the conjunctiva of patients with chronic graft-versus-host disease. Eur J Ophthalmol, 2006;16(1):17-23.
46. Hill JC. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol, 1989;73(2):151-154.
47. Papas AS, et al. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogrens syndrome. Adv Exp Med Biol, 1998;438:973-978.
48. Tsifetaki N, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis, 2003;62(12):1204-1207.
49. Papas AS, et al. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjogren’s Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol, 2004;10(4):169-177.
50. Ono M, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol, 2004;138(1):6-17.
51. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens, 2003;29(2):96-99.
52. Frucht-Pery J, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol, 1993;116(1):88-92.
53. Russo PA, Bouchard CS, Galasso JM. Extended-wear silicone hydrogel soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus- host disease. Eye Contact Lens, 2007;33(3):144-147.
54. Levinson A, Weissman BA, Sachs U. Use of the Bausch & Lomb Soflens Plano T contact lens as a bandage. Am J Optom Physiol Opt, 1977;54(2):97-103.
55. Hovding G. Hydrophilic contact lenses in corneal disorders. Acta Ophthalmol (Copenh), 1984;62(4):566-576.
56. Takahide K, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2007;13(9):1016-1021.
57. Cosar CB, et al. Tarsorrhaphy: clinical experience from a cornea practice. Cornea, 2001;20(8):787-791.
58. Gresset J, Simonet P, Gordon D. Combination of a side shield with an ocular moisture chamber. Am J Optom Physiol Opt, 1984;61(9):610-612.
59. Hart DE, Simko M, Harris E. How to produce moisture chamber eyeglasses for the dry eye patient. J Am Optom Assoc, 1994;65(7):517-522.
60. Murube J, Murube E. Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol, 1996;40(6):463-480.
61. SmartPlug Study Group. Management of complications after insertion of the SmartPlug punctal plug: a study of 28 patients. Ophthalmology, 2006; 113(10):1859 e1–e6.
62. Mazow ML, McCall T, Prager TC. Lodged intracanalicular plugs as a cause of lacrimal obstruction. Ophthal Plast Reconstr Surg, 2007;23(2):138-142.
63. Kiang E, et al. The use of topical cyclosporin A in ocular graft- versus-host-disease. Bone Marrow Transplant, 1998;22(2): 147-151.
64. Lelli GJ, Jr., et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea, 2006;25(6):635-638.
65. Wang Y, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant, 2008; 41(3):293-302.
66. Rocha EM, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant, 2000;25(10):1101-1103.
67. Ogawa Y, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant, 2003;31(7):579-583.
68. Chiang CC, et al. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea, 2007;26(7):861-863.
69. Pinheiro MN, Jr., et al. [Oral flaxseed oil (Linum usitatissimum) in the treatment for dry-eye Sjogren’s syndrome patients]. Arq Bras Oftalmol, 2007;70(4):649-655.
70. Ogawa Y, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea, 2001;20(4): 430-434.
71. Kim H, et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci, 2005;46(2):655-662.